Cytra-k

Cytra-k

Cytra-k Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

There have not been several reports, published and unpublished, concerning nonspecific small-bowel lesions consisting of stenosis, with or without ulceration, associated with the administration of  enteric-coated thiazides with potassium salts.  These lesions may occur with enteric-coated potassium tablets alone or when they are used with nonenteric-coated thiazides, or certain other oral diuretics.  These small-bowel lesions have caused obstruction, hemorrhage, and perforation.  Surgery was frequently required and deaths have occurred.  Based on a large survey of physicians and hospitals, both United States and foreign, the incidence of these lesions is low, and a causal relationship in man has not been definitely established.  Available information tends to implicate enteric-coated potassium salts, although lesions of this type also occur spontaneously.  Therefore, coated potassium-containing formulations should be administered only when indicated, and should be discontinued immediately if abdominal pain, distention, nausea, vomiting, or gastrointestinal bleeding occur.

Large doses may cause hyperkalemia an alkalosis, especially in the presence of renal disease.  Concurrent administration of potassium-containing medication, potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, or cardiac glycosides may lead to toxicity.  Do not exceed recommended dosage.  Discontinue use if adverse reaction occurs.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Cytra-K Oral Solution is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated.  In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine.  It is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable.  This product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose.  This product alkalinizes the urine without producing a systemic alkalosis in recommended dosage.  It is highly palatable, pleasant tasting and tolerable, even when administered for long periods.  Potassium citrate does not neutralize the gastric juice or disturb digestion.

History

There is currently no drug history available for this drug.

Other Information

Rx Only
NDC 60258-003-16


DESCRIPTION
Cytra-K Oral Solution is a stable and pleasant-tasting oral systemic alkalizer containing potassium citrate and citric acid in a sugar-free, non alcoholic base.

CYTRA-K Oral Solution contains in each teaspoonful (5 mL):
Potassium Citrate Monohydrate.................................1100 mg
Citric Acid Monohydrate..............................................334 mg

Each mL contains 2 mEq potassium ion and is equivalent to 2 mEq bicarbonate (HCO 3).

Cytra-k Manufacturers


  • Cypress Pharmaceutical, Inc.
    Cytra-k (Potassium Citrate And Citric Acid) Liquid [Cypress Pharmaceutical, Inc.]

Login To Your Free Account